Treatment with any systemic anti-neoplastic therapy, or investigational therapy within the weeks prior to the initiation of study drug. Biologic (anti-neoplastic agent): patients must be at least days since the completion of therapy prior to registration Patients may not have received paclitaxel, doxorubicin, or cyclophosphamide as anti-neoplastic therapy Concomitant treatment with other anti-neoplastic agents (hormonal therapy acceptable) Biologic (anti-neoplastic agent): at least days since the completion of therapy with a biological agent Treatment with any systemic anti-neoplastic therapy, or investigational therapy within the weeks prior to the initiation of study drug administration. Treatment with any local or systemic anti-neoplastic therapy, radiotherapy (excluding limited palliative radiation), or investigational anticancer agent within days or halflives, whichever is longer, up to a maximum wash-out period of days prior to the initiation of study drug administration Concurrent therapy with other systemic anti-neoplastic or investigational agents No other investigational anti-neoplastic therapy for one month prior to entry in this study No other investigational anti-neoplastic therapy for one month prior to entry in this study Other anti-neoplastic investigational agents currently or within weeks prior to apheresis (i.e. start of protocol therapy) Patients may not be receiving any other anti-neoplastic investigational agents Concomitant treatment with other anti-neoplastic agents, with the exception, when clinically indicated, of prophylaxis in the post-transplantation setting with intrathecal chemotherapy Subject has received biologic agents (e.g. monoclonal antibodies) for anti-neoplastic intent within days prior to first dose of study drug Other anti-neoplastic investigational agents currently or within days prior to apheresis (i.e. start of protocol therapy) Biologic (anti-neoplastic agent) Prior, concomitant or planned treatment with Novo-TTF, EGFR-targeted therapy, bevacizumab, Gliadel wafers or other intratumoral or intracavity anti-neoplastic therapy Biological (anti-neoplastic) therapy: ? days prior to screening. Patients may not be receiving any other anti-neoplastic agents Fewer than days before Cycle Day since administration of hormonal or biological anti-neoplastic agents Patients receiving cytotoxic agent as immunomodulatory therapy for a non neoplastic indication (e.g. methotrexate for rheumatoid arthritis) and who are unable to discontinue such agents within weeks prior to starting treatment Current therapy with other systemic anti-neoplastic or anti-neoplastic investigational agents Current therapy with other systemic anti-neoplastic or anti-neoplastic investigational agents A biologic agent (i.e., monoclonal antibodies) for anti-neoplastic intent within days Steroid therapy for anti-neoplastic intent within days Patients who are currently receiving and responding to a different course of anti-neoplastic therapy, within the limits of acceptable toxicity per standard clinical practice, may not be enrolled to this study Receipt of the following treatment prior to first dose of BGB-: corticosteroids given with anti-neoplastic intent within days, chemotherapy or radiotherapy within weeks, monoclonal antibody within weeks. Patients who are receiving other anti-neoplastic therapy (e.g. chemotherapy, targeted therapy or radiotherapy) concurrently or within weeks of starting study treatment with sonidegib Is currently participating and receiving study therapy with potential anti-neoplastic activity, or has participated in a study of an investigational agent and received study therapy with potential anti-neoplastic activity within weeks of the first dose of treatment ? weeks for local radiation therapy, systemic cytotoxic anticancer therapy, treatment with other anti-neoplastic investigational agents Patients may not have received paclitaxel, doxorubicin, or cyclophosphamide as anti-neoplastic therapy Treatment with any systemic anti-neoplastic therapy, or investigational therapy within the weeks prior to the initiation of study drug. Patients under treatment (or who will have recently been treated) with anti-neoplastic, immunosuppressive or hormonal medications Other anti-neoplastic investigational agents currently or within days prior to apheresis (i.e. start of protocol therapy) Monoclonal antibody (mAb) for direct anti-neoplastic treatment within weeks Patients with no more than prior treatments with systemic anti-neoplastic therapy for CCA. > previous systemic anti-neoplastic regimens for CCA. Received anti-neoplastic monoclonal antibodies within days of the first dose of study drug. Anti-neoplastic agents Participants cannot have received any anti-neoplastic therapy (including radiotherapy, chemotherapy or immunotherapy) after ASCT Current therapy with other systemic anti-neoplastic or anti-neoplastic investigational agents Concomitant use of additional anti-neoplastic agents will not be allowed in this study Must not have received systemic anti-neoplastic therapy, including radiotherapy within days of study treatment Patients receiving other anti-neoplastic agents are excluded Concurrent treatment with other investigational or anti-neoplastic agents Anti-neoplastic treatment less than weeks prior to enrollment, with the exception of hydroxyurea Patient may not receive concomitant cytotoxic anti-neoplastic therapy during treatment; patients may be allowed to use hormonal suppression therapy or bisphosphonates for hypercalcemia Patients who are receiving other anti-neoplastic therapy (e.g. chemotherapy, targeted therapy or radiotherapy) concurrently Subject has received a monoclonal antibody for anti-neoplastic intent within weeks prior to the first dose of study drug. Post ASCT or current therapy with other systemic anti-neoplastic or investigational agents Last dose of systemic anti-neoplastic therapy > days prior to first RO infusion Concomitant treatment with other anti-neoplastic agents, with the exception of hydroxyurea Current receiving any other anti-neoplastic investigational agents Biologic/Immunologic (anti-neoplastic) therapy: It must be at least days since the completion of therapy with a biologic/immunologic agent such as a monoclonal antibody prior to study enrollment and at least days since non-study chemotherapy has been administered, excluding CNS directed therapy as described in Section .. Patients who are receiving other anti-neoplastic therapy (e.g. chemotherapy, targeted therapy or radiotherapy) concurrently or within weeks of starting LDE Current therapy with other systemic anti-neoplastic or anti-neoplastic investigational agents Patients may not be receiving any other investigational agents or active anti-neoplastic therapies Patient has concurrent use of anti-neoplastic agents including investigational therapy Subject has received a biologic agent for anti-neoplastic intent within days prior to the first dose of study drug Biologic (anti-neoplastic agent including retinoids): Last dose given at least days prior to the start date for protocol therapy. Biologic agent (i.e., antibodies) for anti-neoplastic intent within days Steroid therapy for anti-neoplastic intent within days Patients who are receiving other anti-neoplastic therapy (e.g. chemotherapy, targeted therapy, or radiotherapy) concurrently or within weeks of starting treatment Concurrent therapy with other anti-neoplastic or experimental agents The subject is receiving concomitant radiotherapy, chemotherapy, other anti-neoplastic therapy, or investigational therapy (other than the investigational therapy under study) The subject has received radiation therapy, chemotherapy, other anti-neoplastic therapy, or investigational therapy within days prior to first dose of study drug Biologic (anti-neoplastic) agent: At least days since the completion of therapy with a biologic agent; at least half-lives since previous monoclonal antibody therapy All previous treatment (including surgery, radiotherapy and systemic anti-neoplastic therapy) must have been completed at least three weeks prior to study entry and any acute toxicities must have resolved Patients who are receiving other anti-neoplastic therapy (e.g. chemotherapy, targeted therapy or radiotherapy) concurrently or within weeks of starting treatment with LDE Patients currently using anti-neoplastic or anti-tumor agents, including chemotherapy, radiation therapy, immunotherapy, and hormonal anticancer therapy Treatment with any local or systemic anti-neoplastic therapy or any other investigational agent in the weeks prior to study drug administration Subjects must have neurological findings (i.e. loss of consciousness, paresis, cranial neuropathy, etc.), and/or radiological abnormalities in the brain (neoplastic or non-neoplastic in nature) weeks since any oral anti-neoplastic or oral investigational agent Biologic: ? days from anti-neoplastic biologic agent